WO2003027148A8 - Disulfide-reduced neogalactosyl serum albumin and use of radiolabeled derivative thereof for liver imaging - Google Patents

Disulfide-reduced neogalactosyl serum albumin and use of radiolabeled derivative thereof for liver imaging

Info

Publication number
WO2003027148A8
WO2003027148A8 PCT/KR2002/001787 KR0201787W WO03027148A8 WO 2003027148 A8 WO2003027148 A8 WO 2003027148A8 KR 0201787 W KR0201787 W KR 0201787W WO 03027148 A8 WO03027148 A8 WO 03027148A8
Authority
WO
WIPO (PCT)
Prior art keywords
neogalactosyl
serum albumin
disulfide
reduced
liver imaging
Prior art date
Application number
PCT/KR2002/001787
Other languages
French (fr)
Other versions
WO2003027148A1 (en
Inventor
Jae Min Jeong
Jaetae Lee
Original Assignee
Jae Min Jeong
Jaetae Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jae Min Jeong, Jaetae Lee filed Critical Jae Min Jeong
Publication of WO2003027148A1 publication Critical patent/WO2003027148A1/en
Publication of WO2003027148A8 publication Critical patent/WO2003027148A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed are disulfide-reduced neogalactosyl serum albumin and use of its radiolabeled derivative for liver imaging. More particularly, the present invention relates to disulfide-reduced neogalactosyl serum albumin represented by the following Formula 1 and a method of preparing the same, as well as its radiolabeled derivative. Also, the present invention is concerned with a kit for liver imaging, which is capable of radiolabeling neogalactosyl human serum albumin. The radiolabeled compound according to the present invention has excellent stability as well as a high accumulation rate in liver, thereby allowing its application in liver imaging Formula (I), wherein, Ga1, L, A, n, and m are described in detail in the specification.
PCT/KR2002/001787 2001-09-25 2002-09-19 Disulfide-reduced neogalactosyl serum albumin and use of radiolabeled derivative thereof for liver imaging WO2003027148A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR2001/59413 2001-09-25
KR10-2001-0059413A KR100464917B1 (en) 2001-09-25 2001-09-25 Disulfide reduced galactosylated serum albumins and their radioisotope labeled compounds for hepatic function image thereof

Publications (2)

Publication Number Publication Date
WO2003027148A1 WO2003027148A1 (en) 2003-04-03
WO2003027148A8 true WO2003027148A8 (en) 2004-05-06

Family

ID=19714668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2002/001787 WO2003027148A1 (en) 2001-09-25 2002-09-19 Disulfide-reduced neogalactosyl serum albumin and use of radiolabeled derivative thereof for liver imaging

Country Status (2)

Country Link
KR (1) KR100464917B1 (en)
WO (1) WO2003027148A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138531B2 (en) * 2001-10-15 2006-11-21 Kemin Pharma B.V.B.A. Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity
FR2909881A1 (en) * 2006-12-14 2008-06-20 Inst Nat Sante Rech Med NOVEL CONJUGATES FOR USE IN THERAPEUTIC PURPOSES AND / OR AS DIAGNOSTIC AND / OR IMAGING AGENTS AND METHOD FOR PREPARING THE SAME
KR101055700B1 (en) 2009-01-28 2011-08-11 서울대학교산학협력단 Conjugates of Bifunctional Chelating Agents with Mannosyl Phosphorus Albumin and Radioisotope Labeling Compounds for Immune Cell Imaging and Detection
KR101395085B1 (en) * 2010-06-11 2014-05-21 국립암센터 Radioisotope labelled folic acid conjugate compound specific to cancer and sentinel lymph node
KR101879682B1 (en) * 2015-03-11 2018-07-19 서울대학교산학협력단 Albumin-based disease targeting diagnostic or therapeutic nano-platform

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2664509B1 (en) * 1990-07-10 1994-04-15 Lvmh Recherche APPLICATOR DEVICE FOR MORE OR LESS VISCOUS LIQUID PRODUCTS.
US5517125A (en) * 1993-07-09 1996-05-14 Aehr Test Systems, Inc. Reusable die carrier for burn-in and burn-in process

Also Published As

Publication number Publication date
KR20030026153A (en) 2003-03-31
KR100464917B1 (en) 2005-01-06
WO2003027148A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
CA2450690A1 (en) Improved chelator conjugates
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2003016282A3 (en) Substituted 1h-dihydropyrazoles, their preparation and use
WO2004094452A3 (en) Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
CA2506016A1 (en) 3-amino-piperidine derivatives and processes for their preparation
MXPA02011370A (en) Substituted iminoazines.
EP1674452A4 (en) Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor
WO2002062398A3 (en) Radioactively labelled conjugates of phosphonates
WO2003076417A3 (en) Oxo-azabicyclic compounds
EP1380564A4 (en) Binaphtol derivative and process for producing the same
CA2496623A1 (en) Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
EP1634874A4 (en) Imidazolidine derivative
PL363990A1 (en) Arylsulfonamides as antiviral agents
WO2005033066A3 (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
AU8728801A (en) Method and agents on the basis of 2-mercaptopropionic acid amides for durable hair forming and a method for producing same
WO2003027148A8 (en) Disulfide-reduced neogalactosyl serum albumin and use of radiolabeled derivative thereof for liver imaging
CA2362217A1 (en) Process for preparing phenylpyrazole pesticidal intermediates
WO2003053337A3 (en) Therapeutic compositions
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
TR200400293T4 (en) Synthesis of water-soluble 9-dihydro-paclitaxel derivatives of 9-dihydro-13-acetylbaccatin III.
WO2003035651A3 (en) Novel artemisinine derivatives, and uses thereof for treating malaria
WO2003024400A3 (en) Process for the preparation of 1,5-diarylpyrazoles
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
EP1310490A4 (en) Gpr14 antagonist
WO2002053537A8 (en) Process for preparing (±) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 14/2003 UNDER (81) DELETE "KR"

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP